Opinions on the stock are mixed, with 3 analysts rating it as a “buy”, 1 as “overweight”, 0 as “hold”, and 0 as “sell”.
On July 04, 2025, the average trading volume of RADX was 23.19K shares.
RADX stock’s latest price update
The stock price of Radiopharm Theranostics Ltd ADR (NASDAQ: RADX) has dropped by -2.05% compared to previous close of $4.06. Despite this, the company has seen a fall of -15.39% in its stock price over the last five trading days.
RADX’s Market Performance
Radiopharm Theranostics Ltd ADR (RADX) has experienced a -15.39% fall in stock performance for the past week, with a -18.84% drop in the past month, and a -15.03% drop in the past quarter. The volatility ratio for the week is 12.96%, and the volatility levels for the past 30 days are at 12.95% for RADX. The simple moving average for the past 20 days is -16.07% for RADX’s stock, with a -21.15% simple moving average for the past 200 days.
Analysts’ Opinion of RADX
Many brokerage firms have already submitted their reports for RADX stocks, with B. Riley Securities repeating the rating for RADX by listing it as a “Buy”. The predicted price for RADX in the upcoming period, according to B. Riley Securities is $15 based on the research report published on March 12, 2025 of the current year 2025.
RADX Trading at -11.58% from the 50-Day Moving Average
After a stumble in the market that brought RADX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.18% of loss for the given period.
Volatility was left at 12.95%, however, over the last 30 days, the volatility rate increased by 12.96%, as shares sank -22.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.32% lower at present.
During the last 5 trading sessions, RADX fell by -15.39%, in comparison to the 20-day moving average, which settled at $4.74. In addition, Radiopharm Theranostics Ltd ADR saw N/A in overturn over a single year, with a tendency to cut further N/A.
Insider Trading
N/A, the N/A of Radiopharm Theranostics Ltd ADR, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for RADX
Current profitability levels for the company are sitting at:
- -122.38% for the present operating margin
- 1.0% for the gross margin
The net margin for Radiopharm Theranostics Ltd ADR stands at -160.24%. The total capital return value is set at -0.67%. Equity return is now at value -111.73%, with -55.05% for asset returns.
Currently, EBITDA for the company is -44.08 million with net debt to EBITDA at 0.42. When we switch over and look at the enterprise to sales, we see a ratio of -35.87. The receivables turnover for the company is 0.3for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.37.
Conclusion
To sum up, Radiopharm Theranostics Ltd ADR (RADX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
